Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Nov;38(5):411–416. doi: 10.1111/j.1365-2125.1994.tb04375.x

Inhibition of phenobarbitone N-glucosidation by valproate.

I Bernus 1, R G Dickinson 1, W D Hooper 1, M J Eadie 1
PMCID: PMC1364873  PMID: 7893581

Abstract

Plasma phenobarbitone concentrations and daily urinary excretion of phenobarbitone and its metabolites p-hydroxyphenobarbitone (conjugated and unconjugated), and [S]-phenobarbitone-N-glucoside were measured under steady-state conditions in two groups of epileptic patients, (i) taking phenobarbitone with or without other drugs, but not valproate (n = 12), and (ii) taking phenobarbitone with other drugs including valproate (n = 8). Mean steady-state plasma phenobarbitone concentrations were 5.9 mg l-1 higher, relative to drug dose, in the patients taking valproate than in those not taking valproate. Urinary excretion of [S]-phenobarbitone-N-glucoside was significantly lower in the group taking valproate (1.9 +/- s.d. 2.0% of phenobarbitone dose vs 16.2 +/- s.d. 9.9%). Urinary excretion of phenobarbitone (23.7 +/- s.d. 9.8% vs 48.2 +/- s.d. 13.6%) and unconjugated p-hydroxyphenobarbitone (5.7 +/- s.d. 3.9% vs 16.0 +/- s.d. 9.1%) was higher in those taking valproate, while conjugated p-hydroxyphenobarbitone excretion was similar in both groups (8.3 +/- s.d. 4.9% vs 6.5 +/- s.d. 2.9%). Valproate appeared to inhibit both the direct N-glucosidation of phenobarbitone and the O-glucuronidation of p-hydroxyphenobarbitone.

Full text

PDF
414

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. J., Luders H., Pippenger C. Sodium valproate in the treatment of intractable seizure disorders: a clinical and electroencephalographic study. Neurology. 1978 Feb;28(2):152–157. doi: 10.1212/wnl.28.2.152. [DOI] [PubMed] [Google Scholar]
  2. Anderson G. D., Levy R. H. The effect of valproate on the metabolism of phenobarbital in the rat. Pharm Res. 1992 Dec;9(12):1622–1628. doi: 10.1023/a:1015876727795. [DOI] [PubMed] [Google Scholar]
  3. Bernus I., Dickinson R. G., Hooper W. D., Eadie M. J. Urinary excretion of phenobarbitone and its metabolites in chronically treated patients. Eur J Clin Pharmacol. 1994;46(5):473–475. doi: 10.1007/BF00191914. [DOI] [PubMed] [Google Scholar]
  4. Bruni J., Wilder B. J., Perchalski R. J., Hammond E. J., Villarreal H. J. Valproic acid and plasma levels of phenobarbital. Neurology. 1980 Jan;30(1):94–97. doi: 10.1212/wnl.30.1.94. [DOI] [PubMed] [Google Scholar]
  5. Fernandez de Gatta M. R., Alonso Gonzalez A. C., Garcia Sanchez M. J., Dominguez-Gil Hurle A., Santos Borbujo J., Monzon Corral L. Effect of sodium valproate on phenobarbital serum levels in children and adults. Ther Drug Monit. 1986;8(4):416–420. doi: 10.1097/00007691-198612000-00006. [DOI] [PubMed] [Google Scholar]
  6. Gram L., Wulff K., Rasmussen K. E., Flachs H., Würtz-Jorgensen A., Sommerbeck K. W., Lohren V. Valproate sodium: a controlled clinical trial including monitoring of drug levels. Epilepsia. 1977 Jun;18(2):141–148. doi: 10.1111/j.1528-1157.1977.tb04462.x. [DOI] [PubMed] [Google Scholar]
  7. Howell S. R., Hazelton G. A., Klaassen C. D. Depletion of hepatic UDP-glucuronic acid by drugs that are glucuronidated. J Pharmacol Exp Ther. 1986 Mar;236(3):610–614. [PubMed] [Google Scholar]
  8. Kapetanović I. M., Kupferberg H. J., Porter R. J., Theodore W., Schulman E., Penry J. K. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981 Apr;29(4):480–486. doi: 10.1038/clpt.1981.66. [DOI] [PubMed] [Google Scholar]
  9. Patel I. H., Levy R. H., Cutler R. E. Phenobarbital--valporic acid interaction. Clin Pharmacol Ther. 1980 Apr;27(4):515–521. doi: 10.1038/clpt.1980.72. [DOI] [PubMed] [Google Scholar]
  10. Schobben F., van der Kleijn E., Gabreëls F. J. Pharmacokinetics of di-n-propylacetate in epileptic patients. Eur J Clin Pharmacol. 1975 Feb 28;8(2):97–105. doi: 10.1007/BF00561557. [DOI] [PubMed] [Google Scholar]
  11. Soine W. H., Safi H., Westkaemper R. B. Initial studies on the N-glucosylation of phenobarbital by mouse liver microsomes using a radiochemical high-performance liquid chromatographic (HPLC) method. Pharm Res. 1992 May;9(5):613–616. doi: 10.1023/a:1015889707922. [DOI] [PubMed] [Google Scholar]
  12. Soine W. H., Soine P. J., England T. M., Ferkany J. W., Agriesti B. E. Identification of phenobarbital N-glucosides as urinary metabolites of phenobarbital in mice. J Pharm Sci. 1991 Feb;80(2):99–103. doi: 10.1002/jps.2600800202. [DOI] [PubMed] [Google Scholar]
  13. Soine W. H., Soine P. J., England T. M., Welty D. F., Wood J. H. LC determination of the diastereomers of 1-(beta-D-glucopyranosyl)phenobarbital in human urine. J Pharm Biomed Anal. 1990;8(4):365–372. doi: 10.1016/0731-7085(90)80051-p. [DOI] [PubMed] [Google Scholar]
  14. Suganuma T., Ishizaki T., Chiba K., Hori M. The effect of concurrent administration of valproate sodium on phenobarbital plasma concentration/dosage ratio in pediatric patients. J Pediatr. 1981 Aug;99(2):314–317. doi: 10.1016/s0022-3476(81)80488-x. [DOI] [PubMed] [Google Scholar]
  15. Taburet A. M., Aymard P. Valproate glucuronidation by rat liver microsomes. Interaction with parahydroxyphenobarbital. Biochem Pharmacol. 1983 Dec 15;32(24):3859–3861. doi: 10.1016/0006-2952(83)90161-2. [DOI] [PubMed] [Google Scholar]
  16. Tang B. K., Kalow W., Grey A. A. Metabolic fate of phenobarbital in man. N-Glucoside formation. Drug Metab Dispos. 1979 Sep-Oct;7(5):315–318. [PubMed] [Google Scholar]
  17. Vest F. B., Soine W. H., Westkaemper R. B., Soine P. J. Stability of phenobarbital N-glucosides: identification of hydrolysis products and kinetics of decomposition. Pharm Res. 1989 Jun;6(6):458–465. doi: 10.1023/a:1015908221339. [DOI] [PubMed] [Google Scholar]
  18. Whyte M. P., Dekaban A. S. Metabolic fate of phenobarbital. A quantitative study of p-hydroxyphenobarbital elimination in man. Drug Metab Dispos. 1977 Jan-Feb;5(1):63–70. [PubMed] [Google Scholar]
  19. Wilder B. J., Willmore L. J., Bruni J., Villarreal H. J. Valproic acid: interaction with other anticonvulsant drugs. Neurology. 1978 Sep;28(9 Pt 1):892–896. doi: 10.1212/wnl.28.9.892. [DOI] [PubMed] [Google Scholar]
  20. Yuen A. W., Land G., Weatherley B. C., Peck A. W. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992 May;33(5):511–513. doi: 10.1111/j.1365-2125.1992.tb04079.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES